These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 26881236)

  • 1. Incretin-Based Therapy for Prevention of Diabetic Vascular Complications.
    Mima A
    J Diabetes Res; 2016; 2016():1379274. PubMed ID: 26881236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
    van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
    Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence.
    Kawanami D; Matoba K; Sango K; Utsunomiya K
    Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27483245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of protein kinase C activation and the vascular complications of diabetes.
    Das Evcimen N; King GL
    Pharmacol Res; 2007 Jun; 55(6):498-510. PubMed ID: 17574431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiology and pathophysiology of incretins in the kidney.
    von Websky K; Reichetzeder C; Hocher B
    Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):54-60. PubMed ID: 24257158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renoprotective effects of incretin-based drugs: A novel pleiotropic effect of dipeptidyl peptidase-4 inhibitor.
    Kodera R; Shikata K
    J Diabetes Investig; 2016 Jan; 7(1):29-31. PubMed ID: 26816598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential for renoprotection with incretin-based drugs.
    Tanaka T; Higashijima Y; Wada T; Nangaku M
    Kidney Int; 2014 Oct; 86(4):701-11. PubMed ID: 25007170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review.
    Wani JH; John-Kalarickal J; Fonseca VA
    Cardiol Clin; 2008 Nov; 26(4):639-48. PubMed ID: 18929237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence.
    Alicic RZ; Cox EJ; Neumiller JJ; Tuttle KR
    Nat Rev Nephrol; 2021 Apr; 17(4):227-244. PubMed ID: 33219281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular effects of incretins in diabetes.
    Advani A; Bugyei-Twum A; Connelly KA
    Can J Diabetes; 2013 Oct; 37(5):309-14. PubMed ID: 24500557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Will the new molecules be effective in renal and cardiovascular protection in diabetes mellitus and diabetic kidney disease?
    Martinez Martinez-Castelao A; Soler MJ; Navarro-González JF; Górriz JL
    Nefrologia (Engl Ed); 2019; 39(1):3-10. PubMed ID: 30290959
    [No Abstract]   [Full Text] [Related]  

  • 12. Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus.
    Blonde L
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S4-11. PubMed ID: 19952303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular understanding of hyperglycemia's adverse effects for diabetic complications.
    Sheetz MJ; King GL
    JAMA; 2002 Nov; 288(20):2579-88. PubMed ID: 12444865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of glucagon-like peptide-1 on endothelial function.
    Sjöholm A
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():19-25. PubMed ID: 19878258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-ST-elevation myocardial infarction outcomes in patients with type 2 diabetes with non-obstructive coronary artery stenosis: Effects of incretin treatment.
    Marfella R; Sardu C; Calabrò P; Siniscalchi M; Minicucci F; Signoriello G; Balestrieri ML; Mauro C; Rizzo MR; Paolisso G; Barbieri M
    Diabetes Obes Metab; 2018 Mar; 20(3):723-729. PubMed ID: 28950045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy.
    Yamagishi S; Imaizumi T
    Curr Pharm Des; 2005; 11(18):2279-99. PubMed ID: 16022668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dipeptidyl peptidase-4 inhibitors in progressive kidney disease.
    Makino Y; Fujita Y; Haneda M
    Curr Opin Nephrol Hypertens; 2015 Jan; 24(1):67-73. PubMed ID: 25415611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
    Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
    Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin.
    Aroor AR; Manrique-Acevedo C; DeMarco VG
    Cardiovasc Diabetol; 2018 Apr; 17(1):59. PubMed ID: 29669555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Nauck M
    Diabetes Obes Metab; 2016 Mar; 18(3):203-16. PubMed ID: 26489970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.